Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/28/21
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/21
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich's AtaxiaGlobeNewsWire • 05/19/21
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/21
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development ProgramsGlobeNewsWire • 05/06/21
Reata Pharmaceuticals Announces Presentations at Upcoming Investor ConferencesGlobeNewsWire • 05/03/21
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to DeclineZacks Investment Research • 04/29/21
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021GlobeNewsWire • 04/28/21
Strength Seen in Reata Pharmaceuticals, Inc. (RETA): Can Its 3% Jump Turn into More Strength?Zacks Investment Research • 04/28/21
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport SyndromeGlobeNewsWire • 04/26/21
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of DirectorsGlobeNewsWire • 04/15/21
Reata Pharmaceuticals Announces Presentations at Upcoming Medical ConferencesGlobeNewsWire • 03/29/21